Protective Effect of Galangin Methylation Modification Based on Cell Imaging on Inflammatory Lung Injury and Its Molecular Mechanism

Abstract

Background. Recently, inflammation has become a major threat to human health. Studies have confirmed that some Chinese traditional medicine ingredients may effectively interfere with the expression of inflammatory mediators through epigenetic modification, showing a great potential of the application. Objective. To investigate the role of the PPAR/DNMT3A pathway in the reversal of galangin-mediated inflammatory lung injury, promote the development of new anti-inflammatory drugs, reduce the side effects of chemical synthetic drugs on the body, and prove the effectiveness and safety of galangin in inhibiting inflammatory response and injury. Methods. 120 rats were randomly divided into 6 groups: (Group 1) LPS group; (Group 2) LPS + galangin group; (Group 3) LPS + galangin + GW9662 group; (Group 4) LPS + galangin + DNMT3A siRNA group; (Group 5) LPS + galangin + siRNA negative group; (Group 6) control group. The model of inflammatory lung injury was established by intrathecal instillation of LPS in the first five groups and NS in the control group. SD survival rate was recorded every 24 hours after modeling, lasting for 168 hours. The lung tissues were taken 168 hours after the establishment of the model. The pathological morphology of lung tissue was observed after the staining under the light microscope, and the lung dry/wet weight ratio was calculated after drying. After NS was perfused into lung tissue, the lavage fluid was collected and the levels of IL-6 and TNF-a were measured by ELISA. The contents of PPAR, DNMT3A, phosphorylated p65, and ERK in monocytes were detected by the WB method, and the binding contents of p65 and AP-1 in the promoter regions of IL-6 and TNF-a genes were detected by the Chip-qPCR method. Results. Intraperitoneal injection of galangin could inhibit the synthesis of alveolar inflammatory factors (TFs) in the SD model of lung injury induced by LPS, reduce the degree of pathological injury of lung tissue, and improve the survival rate of the SD model. GW9662 can completely reverse the protective effect, while DNMT3A interference can only partially block its protective effect. In addition, galangin could significantly inhibit the LPS-induced expression of p65 and AP-1 in alveolar monocytes and their binding content in the promoter region of inflammatory genes by activating PPAR/DNMT3A pathway. GW9662 could completely reverse the inhibitory effect of galangin. DNMT3A interference could restore the binding content of transcription factors at the promoter of the inflammatory gene but had no significant effect on its synthesis. Conclusion. Galangin can interfere with the binding of transcription factors to inflammatory gene promoters through the methylation modification induced by PPAR/DNMT3A pathway, so as to inhibit the synthesis of inflammatory molecules and reverse inflammatory lung injury.

Mecp2 promotes the anti‐inflammatory effect of alpinetin via epigenetic modification crosstalk

“…Therefore, the PPAR/DNMT3A pathway is considered the main molecular mechanism involved in reversing inflammatory organ damage by alpinetin. 14 , 15 …”

“…Moreover, we found that PPAR activation induced by alpinetin can further promote the synthesis and modification activity of DNA methyltransferase DNMT3A in the nucleus of RAW 246.7 (the macrophage cell line), thus promoting the methylated modification of the IL‐6 promoter and blocked the binding of transcription factors. Therefore, the PPAR/DNMT3A pathway is considered the main molecular mechanism involved in reversing inflammatory organ damage by alpinetin 14,15 …”

“…Therefore, the PPAR/DNMT3A pathway is considered the main molecular mechanism involved in reversing inflammatory organ damage by alpinetin. 14,15 Methyl-CpG-binding protein 2 (Mecp2) is a crucial transcriptional regulator for synaptic function that binds to methylated DNA. 16 Our previous study confirmed that Mecp2 could inhibit the binding of the coactivator p300 to the methylated IL-6 promoter in human embryonic kidney cells.…”